Text Size

Dysregulated Tyrosine Kinase Signaling in Leukemia

This study has been completed.
Sponsor:
Information provided by:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT00277056
First received: January 11, 2006
Last updated: January 6, 2010
Last verified: April 2008
History of Changes
  Purpose

Dysregulated Tyrosine Kinase Signaling in Leukemia


Condition
Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dysregulated Tyrosine Kinase Signaling in Leukemia

Resource links provided by NLM:

MedlinePlus related topics: Leukemia
Drug Information available for: Tyrosine
U.S. FDA Resources

Further study details as provided by University of New Mexico:

Biospecimen Retention:   Samples With DNA

blood bone marrow


Enrollment: 30
Study Start Date: May 2002
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Detailed Description:

Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

people with leukemia

Criteria

Inclusion Criteria:

  • Patients must have newly diagnosed or relapsed leukemia.
  • Patients must sign an informed consent.
  • Patients will not be excluded if they are receiving chemotherapy.
  • Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.
  • Patients must be => 18 years of age.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00277056

Locations
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Principal Investigator: Ian Rabinowitz, MD University of New Mexico
  More Information

No publications provided

Responsible Party: Ian Rabinowitz, MD, University of New Mexico CRTC
ClinicalTrials.gov Identifier: NCT00277056     History of Changes
Other Study ID Numbers: 1602C
Study First Received: January 11, 2006
Last Updated: January 6, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by University of New Mexico:
leukemia

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on May 16, 2013